Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNSA-001 in Parkinson's disease adjunctive to levodopa
ACTRN12620000671965Phase 2Withdrawn
- Sponsor
- Censa Pharmaceuticals
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sepiapterin in Parkinson's disease (PD), sponsored by Censa Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple oral daily doses of CNSA-001 60 mg/kg with food. Planned start Jul 2020; status: withdrawn.
02
Drugs
sepiapterin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12620000671965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000671965.